trial

Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)

NCTId NCT03919994
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 338 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2023-01-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
338 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2019-03-28
Primary completion
2023-01-04
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
—

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Alkermes Medical Director, MDStudy Director

Sites

57 total
Tucson, United StatesCosta Mesa, United StatesEl Cajon, United StatesGranada Hills, United StatesOceanside, United StatesPanorama City, United StatesSan Bernardino, United StatesDayville, United StatesHialeah, United StatesHialeah, United StatesLauderdale Lakes, United StatesMiami, United States

Facts & assertions

4 sourced
Enrollment
338
Phase
NA
Primary Completion Date
2023-01-04
Status
COMPLETED
relationships
The graph out of here
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Alkermes Medical Director, MD
person